“利沃素”治疗非酒精性脂肪性肝炎患者1例及文献复习

Liversol treatment of non-alcoholic steatohepatitis:a case report and literature review

目前,以非酒精性脂肪性肝病(non-alcoholic fatty liver disease,NAFLD)为适应证的临床治疗药物研发活跃,但尚无正式批准上市的药物。现普遍认为血清丙氨酸氨基转移酶(alanine aminotransferase,ALT)升高,伴或不伴有高胆固醇血症、高甘油三酯血症,甚至血糖水平升高的非酒精性脂肪性肝炎(non-alcoholic steatohepatitis,NASH)患者均应给予干预。生活方式改变和功能医学干预是目前的主要手段。现对1例NASH患者应用功能性医学产品"利沃素(Liversol)"治疗的临床疗效进行报道。通过对本病例的报道和相关文献的复习,以期对NASH及其干预和治疗新措施有更深入的认识。

Currently,the research and development of clinical therapeutic drugs with the indication of non-alcoholic fatty liver disease(NAFLD)is active,but there is no officially approved drug on the market.It is generally believed that the NASH patients with increased serum alanine aminotransferase(ALT),hypercholesterolemia,hypertriglyceridemia and even elevated blood glucose level should be intervened.Life style modification and functional medicine are the main intervened methods.This paper reported the clinical effects of a case with NASH treated with the functional medicine product"Liversol".Through this report and the review of relevant literature,we hope to have a deeper understanding of NAFLD and its treatment.